BELLUS Health is a clinical stage biotechnology company focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate – BLU-5937 – is currently in phase 2 development in both refractory chronic cough and chronic pruritus associated with atopic dermatitis.
We invite you to visit our investors’ relations page, including our Annual Information Form, to obtain more information about BELLUS Health.
P2X3 receptors are trimeric channels that are expressed in sensory receptors throughout the body and play an important role in sensory hypersensitization. It is thought that when P2X3 receptors in the esophagus become oversensitized, a signal is sent to the brain resulting in the urge to cough.
In our Phase 2a RELIEF clinical trial, our P2X3 antagonist, BLU-5937, showed strong proof-of-concept signals in placebo-adjusted reduction in cough frequency in high cough count patients, with little to no adverse events.